STUB1 disrupts multiple pathogenic T cell lineages through distinct ubiquitination pathways and modulates the immune microenvironment in RA, thereby emerging as a highly attractive therapeutic target for RA [337]. Here, STUB1 is linked to rheumatoid arthritis.